Schedule for Rating Disabilities; AL Amyloidosis (Primary Amyloidosis), 65279-65281 [2010-26661]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 204 / Friday, October 22, 2010 / Proposed Rules
therefore, preparation of an
environmental impact statement will
not be required. After the comment
period, an environmental assessment
will be prepared and it may be reviewed
at the District office listed at the end of
the FOR FURTHER INFORMATION CONTACT,
above.
d. Unfunded Mandates Act. The
proposed rule does not impose an
enforceable duty among the private
sector and, therefore, is not a Federal
private sector mandate and is not
subject to the requirements of Section
202 or 205 of the Unfunded Mandates
Reform Act (Pub. L. 104–4, 109 Stat. 48,
2 U.S.C. 1501 et seq.). We have also
found under Section 203 of the Act, that
small governments will not be
significantly or uniquely affected by this
proposed rule.
List of Subjects in 33 CFR Part 334
Danger zones, Navigation (water),
Restricted areas, Waterways.
For the reasons set out in the
preamble, the Corps proposes to amend
33 CFR part 334 as follows:
or person shall enter the area during the
scheduled block training session except
for such vessels as may be directed by
the enforcing agency to enter on
assigned duties. The area will be
patrolled and vessels ‘‘buzzed’’ by the
patrol plane prior to the conduct of
operations in the area. Vessels or
personnel which have inadvertently
entered the danger zone shall leave the
area immediately upon being so warned.
*
*
*
*
*
Dated: October 8, 2010.
Michael G. Ensch,
Chief, Operations, Directorate of Civil Works.
[FR Doc. 2010–26442 Filed 10–21–10; 8:45 am]
BILLING CODE 3720–58–P
DEPARTMENT OF VETERANS
AFFAIRS
38 CFR Part 4
RIN 2900–AN75
Schedule for Rating Disabilities; AL
Amyloidosis (Primary Amyloidosis)
PART 334—DANGER ZONE AND
RESTRICTED AREA REGULATIONS
AGENCY:
1. The authority citation for 33 CFR
part 334 continues to read as follows:
SUMMARY:
ACTION:
Authority: 40 Stat. 266 (33 U.S.C. 1) and
40 Stat. 892 (33 U.S.C. 3).
2. In § 334.420 add paragraphs
(b)(1)(v) and (b)(2)(iii) to read as follows:
§ 334.420 Pamlico Sound and adjacent
waters, N.C.; danger zones for Marine
Corps operations.
emcdonald on DSK2BSOYB1PROD with PROPOSALS
*
*
*
*
*
(b) * * *
(1) * * *
(v) The waters within a circular band
with an inner radius of 1.8 statute miles
and an outer radius of 2.5 statute miles
having its center at latitude 35°02′12″,
longitude 76°28′00″.
(2) * * *
(iii) The areas described in paragraph
(b)(1)(v) of this section shall be used as
a strafing area. Practice and dummy
ammunition will be used. Operations
will be conducted on five consecutive
days (Monday through Friday) per
month during the months of February
through November between the hours of
4 p.m. to 11 p.m. The block training
dates will be scheduled two weeks in
advance of the actual training start date.
Marine Corps Air Station, Cherry Point
will have a call-in number for public
use to provide information on the
current use of the training area. The
Notification to Mariners System will
also be utilized to inform the public on
the status of the training area. No vessel
VerDate Mar<15>2010
17:19 Oct 21, 2010
Jkt 223001
Department of Veterans Affairs.
Proposed rule.
This document proposes to
amend the Department of Veterans
Affairs (VA) Schedule for Rating
Disabilities (rating schedule) by
updating the schedule of ratings for the
hemic and lymphatic systems to include
AL amyloidosis. This regulatory action
is necessary to add AL amyloidosis as
one of the disease conditions and
establish criteria for disability
evaluation to fully implement the
decision by the Secretary of Veterans
Affairs to grant presumptive service
connection based on herbicide exposure
for this disease. The intended effects are
to provide consistency in disability
ratings and to ease tracking of AL
amyloidosis for statistical analysis.
DATES: Comments must be received by
VA on or before December 21, 2010.
ADDRESSES: Written comments may be
submitted through https://
www.Regulations.gov; by mail or handdelivery to Director, Regulations
Management (02REG), Department of
Veterans Affairs, 810 Vermont Ave.,
NW., Room 1068, Washington, DC
20420; or by fax to (202) 273–9026.
Comments should indicate that they are
submitted in response to ‘‘RIN 2900–
AN75—Schedule for Rating Disabilities;
AL Amyloidosis (Primary
Amyloidosis).’’ All comments received
will be available for public inspection in
the Office of Regulation Policy and
Management, Room 1063B, between the
PO 00000
Frm 00031
Fmt 4702
Sfmt 4702
65279
hours of 8 a.m. and 4:30 p.m., Monday
through Friday (except holidays). Please
call (202) 461–4902 for an appointment.
(This is not a toll-free number.) In
addition, during the comment period,
comments are available online through
the Federal Docket Management System
(FDMS) at https://www.Regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Thomas J. Kniffen, Chief, Regulations
Staff (211D), Compensation and Pension
Service, Veterans Benefits
Administration, Department of Veterans
Affairs, 810 Vermont Avenue, NW.,
Washington, DC 20420, (202) 461–9725.
(This is not a toll-free number.)
SUPPLEMENTARY INFORMATION: A final
rule was published in the Federal
Register at 74 FR 21258 amending 38
CFR 3.309(e) by adding AL amyloidosis
to the list of diseases associated with
exposure to certain herbicide agents.
Currently, the rating schedule does not
have a diagnostic code for AL
amyloidosis. As an unlisted condition,
it is rated by analogy to non-Hodgkin’s
lymphoma using the ‘‘built-up’’
diagnostic code 7799–7715. However,
AL amyloidosis is not part of the group
of diseases under the non-Hodgkin’s
lymphoma classification, but a disorder
of the bone marrow characterized by the
accumulation and deposition of
abnormal, insoluble proteins called light
chain amyloid proteins in any organ of
the body, interfering with the structure
and function of the organ. Therefore, AL
amyloidosis requires a set of evaluation
criteria with a unique diagnostic code,
which will serve as a basis for disability
rating. VA proposes a regulation that
would amend the rating schedule by
adding rating guidance and a diagnostic
code specifically for AL amyloidosis.
AL amyloidosis is a seriously
disabling, progressive, and incurable
condition. It is usually fatal within 1 to
2 years of diagnosis. Because of its rarity
and rapid progression, AL amyloidosis
may not be diagnosed until it has
resulted in considerable multi-organ
damage (to heart, kidney, liver, spleen,
intestine, etc.). At the time of diagnosis,
the most common findings are nephrotic
syndrome with or without renal
insufficiency, congestive
cardiomyopathy, peripheral neuropathy,
and hepatomegaly. The extent of the
disease limits the specific types of
treatments that can be used. Stem cell
transplantation with high dose
chemotherapy, an aggressive and risky
treatment with serious side effects and
a significant mortality rate, can be used
in a limited number of patients who
meet the criteria to undergo such severe
treatment. This treatment has shown
promise in prolonging life but does not
E:\FR\FM\22OCP1.SGM
22OCP1
65280
Federal Register / Vol. 75, No. 204 / Friday, October 22, 2010 / Proposed Rules
emcdonald on DSK2BSOYB1PROD with PROPOSALS
cure the disease. Accumulations of
amyloid in a specific area of the body
can sometimes be removed surgically.
Organ transplants (for example, of a
kidney or the heart) have extended the
lives of a small number of people with
organ failure due to amyloidosis but
eventually the transplanted organ
accumulates amyloid. In general,
treatment can slow the course of the
disease and help alleviate the symptoms
of organ damage, but it is not curative.
AL amyloidosis is a disease most
closely aligned with other diseases of
the hemic and lymphatic systems.
Therefore, VA proposes diagnostic code
7717 for AL amyloidosis because it is
the first available diagnostic code in the
Hemic and Lymphatic Systems listed in
§ 4.117.
VA proposes to assign a 100 percent
rating because the disease is incurable
and progressive, generally causing death
in a few years. While AL amyloidosis
may or may not be totally disabling at
the time of diagnosis or time of claim for
VA compensation, its clinical course is
usually associated with rapid disease
progression and involvement of
multiple organ systems. The usual cause
of death is cardiac, hepatic, or renal
failure, or infection. The median
survival rate for AL amyloidosis is
12–18 months in the United States.
Providing a 100-percent evaluation in
all cases would obviate the need to
reassess and reevaluate veterans with
AL amyloidosis repeatedly over a short
period of time. Because of the poor
prognosis, no follow-up examination
will be required for re-evaluation of this
disability rating.
We also propose to refer to AL
amyloidosis as ‘‘primary amyloidosis’’,
which is another common name for the
same disease. Although the disease may
also be identified as ‘‘immunocytederived amyloidosis’’ and ‘‘light chainrelated amyloidosis’’, these terms for the
disease are much less common.
Therefore, we propose not to include
them under diagnostic code 7717
because their inclusion would not be
useful to the public or VA personnel.
Finally, we propose to amend 38 CFR
Part 4, Appendices A, B, and C to reflect
the proposed addition of diagnostic
code 7717 for AL amyloidosis to the
rating schedule.
Regulatory Flexibility Act
The Secretary hereby certifies that
this proposed rule would not have a
significant economic impact on a
substantial number of small entities as
they are defined in the Regulatory
Flexibility Act, 5 U.S.C. 601 et seq. This
proposed rule will not directly affect
VerDate Mar<15>2010
17:19 Oct 21, 2010
Jkt 223001
small entities. Only VA beneficiaries
will be directly affected. Therefore,
pursuant to 5 U.S.C. 605(b), this
amendment is exempt from the initial
and final regulatory flexibility analysis
requirements of sections 603 and 604.
Executive Order 12866
Executive Order 12866 directs
agencies to assess all costs and benefits
of available regulatory alternatives and,
when regulation is necessary, to select
regulatory approaches that maximize
net benefits (including potential
economic, environmental, public health
and safety, and other advantages;
distributive impacts; and equity). The
Executive Order classifies a ‘‘significant
regulatory action,’’ requiring review by
the Office of Management and Budget
(OMB) unless OMB waives such review,
as any regulatory action that is likely to
result in a rule that may: (1) Have an
annual effect on the economy of $100
million or more, or adversely affect in
a material way the economy, a sector of
the economy, productivity, competition,
jobs, the environment, public health or
safety, or State, local, or Tribal
governments or communities; (2) create
a serious inconsistency or otherwise
interfere with an action taken or
planned by another agency; (3)
materially alter the budgetary impact of
entitlements, grants, user fees, or loan
programs or the rights and obligations of
recipients thereof; or (4) raise novel
legal or policy issues arising out of legal
mandates, the President’s priorities, or
the principles set forth in the Executive
Order.
The economic, interagency,
budgetary, legal, and policy
implications of this proposed rule have
been examined and it has been
determined not to be a significant
regulatory action under Executive Order
12866.
Unfunded Mandates
The Unfunded Mandates Reform Act
of 1995 requires, at 2 U.S.C. 1532, that
agencies prepare an assessment of
anticipated costs and benefits before
issuing any rule that may result in the
expenditure by State, local, and Tribal
governments, in the aggregate, or by the
private sector, of $100 million or more
(adjusted annually for inflation) in any
1 year. This proposed rule would have
no such effect on State, local, and Tribal
governments, or on the private sector.
Catalog of Federal Domestic Assistance
Numbers and Titles
The Catalog of Federal Domestic
Assistance program numbers and titles
for this proposal are 64.104, Pension for
Non-Service-Connected Disability for
PO 00000
Frm 00032
Fmt 4702
Sfmt 4702
Veterans, and 64.109, Veterans
Compensation for Service-Connected
Disability.
Paperwork Reduction Act
This action contains no provisions
constituting a collection of information
under the Paperwork Reduction Act
(44 U.S.C. 3501 et seq.).
Signing Authority
The Secretary of Veterans Affairs, or
designee, approved this document and
authorized the undersigned to sign and
submit the document to the Office of the
Federal Register for publication
electronically as an official document of
the Department of Veterans Affairs. John
R. Gingrich, Chief of Staff, Department
of Veterans Affairs, approved this
document on October 4, 2010, for
publication.
List of Subjects in 38 CFR Part 4
Disability benefits, Pensions,
Veterans.
Dated: October 18, 2010.
Robert C. McFetridge,
Director, Regulation Policy and Management,
Office of the General Counsel, Department
of Veterans Affairs.
For the reasons stated in the
preamble, the Department of Veterans
Affairs proposes to amend 38 CFR part
4 as set forth below:
PART 4—SCHEDULE FOR RATING
DISABILITIES
1. The authority citation for part 4
continues to read as follows:
Authority: 38 U.S.C. 1155, unless
otherwise noted.
Subpart B—Disability Ratings
§ 4.117
[Amended]
2. In § 4.117, add diagnostic code
7717, immediately following the note at
the end of diagnostic code 7716, to read
as follows:
§ 4.117 Schedule of ratings—hemic and
lymphatic systems.
Rating
*
*
*
*
7717 AL amyloidosis (primary
amyloidosis) ..........................
*
*
*
*
*
100
*
Appendix A to Part 4 [Amended]
3. In Appendix A to Part 4, under Sec.
4.117, add diagnostic code 7717 in numerical
order (following diagnostic code number
7716) to the table to read as follows:
E:\FR\FM\22OCP1.SGM
22OCP1
65281
Federal Register / Vol. 75, No. 204 / Friday, October 22, 2010 / Proposed Rules
APPENDIX A TO PART 4—TABLE OF AMENDMENTS AND EFFECTIVE DATES SINCE 1946
Diagnostic
Code No.
Sec.
*
*
*
*
*
*
*
*
*
4.117
*
*
*
*
Added [Date 30 days after date of publication of the final rule in the Federal Register].
7717
Appendix B to Part 4 [Amended]
4. In Appendix B to Part 4 add diagnostic
code 7717 to the table in numerical order
(following the entry for diagnostic code
number 7716) and its disability entry ‘‘AL
*
amyloidosis (primary amyloidosis)’’ to read
as follows:
APPENDIX B TO PART 4—NUMERICAL INDEX OF DISABILITIES
Diagnostic Code No.
*
*
*
*
*
*
*
THE HEMIC AND LYMPHATIC SYSTEMS
*
*
*
7717 .................................... AL amyloidosis (primary amyloidosis).
*
*
Appendix C to Part 4 [Amended]
5. Appendix C to Part 4 is amended by
adding in alphabetical order (following
‘‘Agranulocytosis’’) a new entry ‘‘AL
amyloidosis’’ and its diagnostic code number
‘‘7717’’ to read as follows:
APPENDIX C TO PART 4—
ALPHABETICAL INDEX OF DISABILITIES
Diagnostic
Code No.
*
*
*
AL amyloidosis .....................
*
*
*
*
*
7717
*
*
[FR Doc. 2010–26661 Filed 10–21–10; 8:45 am]
BILLING CODE 8320–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
emcdonald on DSK2BSOYB1PROD with PROPOSALS
42 CFR Part 84
[Docket Numbers NIOSH–221, NIOSH–082A,
NIOSH–147]
Public Meeting To Discuss NIOSH’s
Respirator Standards Development
Efforts
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
AGENCY:
VerDate Mar<15>2010
17:19 Oct 21, 2010
Jkt 223001
*
*
*
*
*
*
*
*
*
and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of a public meeting.
The National Institute for
Occupational Safety and Health
(NIOSH), National Personal Protective
Technology Laboratory (NPPTL), will
conduct a public meeting to discuss
current respirator standards
development projects, including the
NIOSH Regulatory Agenda for updating
42 CFR part 84, CBRN Combination
Unit Respirator Performance
Requirements, and the NIOSH policy on
SCBA ‘‘Buddy-Breathing’’. There will be
an opportunity for discussion following
each topic’s presentations.
DATES: The public meeting will be held
8:30 a.m. to 5 p.m., December 9, 2010.
On-site registration will be held
beginning at 7:45 a.m.
ADDRESSES: The public meeting will be
held at Hyatt Regency Pittsburgh
International Airport, 1111 Airport
Boulevard, Pittsburgh, PA 15231,
telephone 800–233–1234.
FOR FURTHER INFORMATION CONTACT:
Jonathan Szalajda, NPPTL, Policy and
Standards Development Branch Chief,
P.O. Box 18070, 626 Cochrans Mill
Road, Pittsburgh, PA 15236, telephone
412–386–5200, fax 412–386–4089,
E-mail npptlevents@cdc.gov.
SUPPLEMENTARY INFORMATION:
Status: The meeting will be open to
the public, limited only by the space
SUMMARY:
PO 00000
Frm 00033
Fmt 4702
Sfmt 4702
available. The meeting room
accommodates approximately 125
people.
Instructions: Requests to make
presentations at the public meeting
should be mailed to the NIOSH Docket
Officer, Robert A. Taft Laboratories,
MS–C34, 4676 Columbia Parkway,
Cincinnati, Ohio 45226. Requests may
also be submitted by telephone
513–533–8611, fax 513–533–8285, or
e-mailed to niocindocket@cdc.gov. All
requests to present should contain the
name, address, and telephone number,
relevant business affiliations of the
presenter, topic of the presentation, and
the approximate time requested for the
presentation. Oral presentations should
be limited to 15 minutes.
After reviewing the requests for
presentations, NIOSH will notify the
presenters that their presentations are
scheduled. If a participant is not present
when his/her presentation is scheduled
to begin, the remaining participants will
be heard in order. At the conclusion of
the meeting, an attempt will be made to
allow presentations by scheduled
participants who missed their assigned
times. Attendees who wish to speak but
did not submit a request for the
opportunity to make a presentation may
be given this opportunity at the
conclusion of the meeting, at the
discretion of the presiding officer.
This meeting will also be using
Audio/Live Meeting Conferencing,
E:\FR\FM\22OCP1.SGM
22OCP1
]]>Agencies
[Federal Register Volume 75, Number 204 (Friday, October 22, 2010)]
[Proposed Rules]
[Pages 65279-65281]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26661]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
38 CFR Part 4
RIN 2900-AN75
Schedule for Rating Disabilities; AL Amyloidosis (Primary
Amyloidosis)
AGENCY: Department of Veterans Affairs.
ACTION: Proposed rule.
-----------------------------------------------------------------------
SUMMARY: This document proposes to amend the Department of Veterans
Affairs (VA) Schedule for Rating Disabilities (rating schedule) by
updating the schedule of ratings for the hemic and lymphatic systems to
include AL amyloidosis. This regulatory action is necessary to add AL
amyloidosis as one of the disease conditions and establish criteria for
disability evaluation to fully implement the decision by the Secretary
of Veterans Affairs to grant presumptive service connection based on
herbicide exposure for this disease. The intended effects are to
provide consistency in disability ratings and to ease tracking of AL
amyloidosis for statistical analysis.
DATES: Comments must be received by VA on or before December 21, 2010.
ADDRESSES: Written comments may be submitted through https://www.Regulations.gov; by mail or hand-delivery to Director, Regulations
Management (02REG), Department of Veterans Affairs, 810 Vermont Ave.,
NW., Room 1068, Washington, DC 20420; or by fax to (202) 273-9026.
Comments should indicate that they are submitted in response to ``RIN
2900-AN75--Schedule for Rating Disabilities; AL Amyloidosis (Primary
Amyloidosis).'' All comments received will be available for public
inspection in the Office of Regulation Policy and Management, Room
1063B, between the hours of 8 a.m. and 4:30 p.m., Monday through Friday
(except holidays). Please call (202) 461-4902 for an appointment. (This
is not a toll-free number.) In addition, during the comment period,
comments are available online through the Federal Docket Management
System (FDMS) at https://www.Regulations.gov.
FOR FURTHER INFORMATION CONTACT: Thomas J. Kniffen, Chief, Regulations
Staff (211D), Compensation and Pension Service, Veterans Benefits
Administration, Department of Veterans Affairs, 810 Vermont Avenue,
NW., Washington, DC 20420, (202) 461-9725. (This is not a toll-free
number.)
SUPPLEMENTARY INFORMATION: A final rule was published in the Federal
Register at 74 FR 21258 amending 38 CFR 3.309(e) by adding AL
amyloidosis to the list of diseases associated with exposure to certain
herbicide agents. Currently, the rating schedule does not have a
diagnostic code for AL amyloidosis. As an unlisted condition, it is
rated by analogy to non-Hodgkin's lymphoma using the ``built-up''
diagnostic code 7799-7715. However, AL amyloidosis is not part of the
group of diseases under the non-Hodgkin's lymphoma classification, but
a disorder of the bone marrow characterized by the accumulation and
deposition of abnormal, insoluble proteins called light chain amyloid
proteins in any organ of the body, interfering with the structure and
function of the organ. Therefore, AL amyloidosis requires a set of
evaluation criteria with a unique diagnostic code, which will serve as
a basis for disability rating. VA proposes a regulation that would
amend the rating schedule by adding rating guidance and a diagnostic
code specifically for AL amyloidosis.
AL amyloidosis is a seriously disabling, progressive, and incurable
condition. It is usually fatal within 1 to 2 years of diagnosis.
Because of its rarity and rapid progression, AL amyloidosis may not be
diagnosed until it has resulted in considerable multi-organ damage (to
heart, kidney, liver, spleen, intestine, etc.). At the time of
diagnosis, the most common findings are nephrotic syndrome with or
without renal insufficiency, congestive cardiomyopathy, peripheral
neuropathy, and hepatomegaly. The extent of the disease limits the
specific types of treatments that can be used. Stem cell
transplantation with high dose chemotherapy, an aggressive and risky
treatment with serious side effects and a significant mortality rate,
can be used in a limited number of patients who meet the criteria to
undergo such severe treatment. This treatment has shown promise in
prolonging life but does not
[[Page 65280]]
cure the disease. Accumulations of amyloid in a specific area of the
body can sometimes be removed surgically. Organ transplants (for
example, of a kidney or the heart) have extended the lives of a small
number of people with organ failure due to amyloidosis but eventually
the transplanted organ accumulates amyloid. In general, treatment can
slow the course of the disease and help alleviate the symptoms of organ
damage, but it is not curative.
AL amyloidosis is a disease most closely aligned with other
diseases of the hemic and lymphatic systems. Therefore, VA proposes
diagnostic code 7717 for AL amyloidosis because it is the first
available diagnostic code in the Hemic and Lymphatic Systems listed in
Sec. 4.117.
VA proposes to assign a 100 percent rating because the disease is
incurable and progressive, generally causing death in a few years.
While AL amyloidosis may or may not be totally disabling at the time of
diagnosis or time of claim for VA compensation, its clinical course is
usually associated with rapid disease progression and involvement of
multiple organ systems. The usual cause of death is cardiac, hepatic,
or renal failure, or infection. The median survival rate for AL
amyloidosis is 12-18 months in the United States. Providing a 100-
percent evaluation in all cases would obviate the need to reassess and
reevaluate veterans with AL amyloidosis repeatedly over a short period
of time. Because of the poor prognosis, no follow-up examination will
be required for re-evaluation of this disability rating.
We also propose to refer to AL amyloidosis as ``primary
amyloidosis'', which is another common name for the same disease.
Although the disease may also be identified as ``immunocyte-derived
amyloidosis'' and ``light chain-related amyloidosis'', these terms for
the disease are much less common. Therefore, we propose not to include
them under diagnostic code 7717 because their inclusion would not be
useful to the public or VA personnel.
Finally, we propose to amend 38 CFR Part 4, Appendices A, B, and C
to reflect the proposed addition of diagnostic code 7717 for AL
amyloidosis to the rating schedule.
Regulatory Flexibility Act
The Secretary hereby certifies that this proposed rule would not
have a significant economic impact on a substantial number of small
entities as they are defined in the Regulatory Flexibility Act, 5
U.S.C. 601 et seq. This proposed rule will not directly affect small
entities. Only VA beneficiaries will be directly affected. Therefore,
pursuant to 5 U.S.C. 605(b), this amendment is exempt from the initial
and final regulatory flexibility analysis requirements of sections 603
and 604.
Executive Order 12866
Executive Order 12866 directs agencies to assess all costs and
benefits of available regulatory alternatives and, when regulation is
necessary, to select regulatory approaches that maximize net benefits
(including potential economic, environmental, public health and safety,
and other advantages; distributive impacts; and equity). The Executive
Order classifies a ``significant regulatory action,'' requiring review
by the Office of Management and Budget (OMB) unless OMB waives such
review, as any regulatory action that is likely to result in a rule
that may: (1) Have an annual effect on the economy of $100 million or
more, or adversely affect in a material way the economy, a sector of
the economy, productivity, competition, jobs, the environment, public
health or safety, or State, local, or Tribal governments or
communities; (2) create a serious inconsistency or otherwise interfere
with an action taken or planned by another agency; (3) materially alter
the budgetary impact of entitlements, grants, user fees, or loan
programs or the rights and obligations of recipients thereof; or (4)
raise novel legal or policy issues arising out of legal mandates, the
President's priorities, or the principles set forth in the Executive
Order.
The economic, interagency, budgetary, legal, and policy
implications of this proposed rule have been examined and it has been
determined not to be a significant regulatory action under Executive
Order 12866.
Unfunded Mandates
The Unfunded Mandates Reform Act of 1995 requires, at 2 U.S.C.
1532, that agencies prepare an assessment of anticipated costs and
benefits before issuing any rule that may result in the expenditure by
State, local, and Tribal governments, in the aggregate, or by the
private sector, of $100 million or more (adjusted annually for
inflation) in any 1 year. This proposed rule would have no such effect
on State, local, and Tribal governments, or on the private sector.
Catalog of Federal Domestic Assistance Numbers and Titles
The Catalog of Federal Domestic Assistance program numbers and
titles for this proposal are 64.104, Pension for Non-Service-Connected
Disability for Veterans, and 64.109, Veterans Compensation for Service-
Connected Disability.
Paperwork Reduction Act
This action contains no provisions constituting a collection of
information under the Paperwork Reduction Act (44 U.S.C. 3501 et seq.).
Signing Authority
The Secretary of Veterans Affairs, or designee, approved this
document and authorized the undersigned to sign and submit the document
to the Office of the Federal Register for publication electronically as
an official document of the Department of Veterans Affairs. John R.
Gingrich, Chief of Staff, Department of Veterans Affairs, approved this
document on October 4, 2010, for publication.
List of Subjects in 38 CFR Part 4
Disability benefits, Pensions, Veterans.
Dated: October 18, 2010.
Robert C. McFetridge,
Director, Regulation Policy and Management, Office of the General
Counsel, Department of Veterans Affairs.
For the reasons stated in the preamble, the Department of Veterans
Affairs proposes to amend 38 CFR part 4 as set forth below:
PART 4--SCHEDULE FOR RATING DISABILITIES
1. The authority citation for part 4 continues to read as follows:
Authority: 38 U.S.C. 1155, unless otherwise noted.
Subpart B--Disability Ratings
Sec. 4.117 [Amended]
2. In Sec. 4.117, add diagnostic code 7717, immediately following
the note at the end of diagnostic code 7716, to read as follows:
Sec. 4.117 Schedule of ratings--hemic and lymphatic systems.
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
* * * * *
7717 AL amyloidosis (primary amyloidosis).................. 100
* * * * *
------------------------------------------------------------------------
Appendix A to Part 4 [Amended]
3. In Appendix A to Part 4, under Sec. 4.117, add diagnostic
code 7717 in numerical order (following diagnostic code number 7716)
to the table to read as follows:
[[Page 65281]]
Appendix A to Part 4--Table of Amendments and Effective Dates Since 1946
------------------------------------------------------------------------
Diagnostic
Sec. Code No.
------------------------------------------------------------------------
* * * * * * *
4.117
* * * * * * *
7717 .............. Added [Date 30 days
after date of
publication of the
final rule in the
Federal Register].
------------------------------------------------------------------------
Appendix B to Part 4 [Amended]
4. In Appendix B to Part 4 add diagnostic code 7717 to the table
in numerical order (following the entry for diagnostic code number
7716) and its disability entry ``AL amyloidosis (primary
amyloidosis)'' to read as follows:
Appendix B to Part 4--Numerical Index of Disabilities
------------------------------------------------------------------------
Diagnostic Code No.
------------------------------------------------------------------------
* * * * * * *
------------------------------------------------------------------------
THE HEMIC AND LYMPHATIC SYSTEMS
------------------------------------------------------------------------
* * * * * * *
7717...................................... AL amyloidosis (primary
amyloidosis).
* * * * * * *
------------------------------------------------------------------------
Appendix C to Part 4 [Amended]
5. Appendix C to Part 4 is amended by adding in alphabetical
order (following ``Agranulocytosis'') a new entry ``AL amyloidosis''
and its diagnostic code number ``7717'' to read as follows:
Appendix C to Part 4--Alphabetical Index of Disabilities
------------------------------------------------------------------------
Diagnostic
Code No.
------------------------------------------------------------------------
* * * * *
AL amyloidosis.......................................... 7717
* * * * *
------------------------------------------------------------------------
[FR Doc. 2010-26661 Filed 10-21-10; 8:45 am]
BILLING CODE 8320-01-P
